These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15131050)

  • 1. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
    Mehrotra J; Vali M; McVeigh M; Kominsky SL; Fackler MJ; Lahti-Domenici J; Polyak K; Sacchi N; Garrett-Mayer E; Argani P; Sukumar S
    Clin Cancer Res; 2004 May; 10(9):3104-9. PubMed ID: 15131050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
    Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
    Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
    Van der Auwera I; Bovie C; Svensson C; Limame R; Trinh XB; van Dam P; Van Laere SJ; Van Marck E; Vermeulen PB; Dirix LY
    Cancer Biol Ther; 2009 Dec; 8(23):2252-9. PubMed ID: 19829046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
    Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
    Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation profiling of distant breast cancer metastases.
    Schrijver WA; Jiwa LS; van Diest PJ; Moelans CB
    Breast Cancer Res Treat; 2015 May; 151(1):41-55. PubMed ID: 25841351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
    Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
    Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.
    Locke I; Kote-Jarai Z; Fackler MJ; Bancroft E; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
    Breast Cancer Res; 2007; 9(1):R20. PubMed ID: 17324252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females.
    Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Al-Harbi NO; Hassan ZK; Alsheikh A; Al Theyab AI; Aldelemy ML; Sayed-Ahmed MM
    Asian Pac J Cancer Prev; 2015; 16(2):541-9. PubMed ID: 25684485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
    Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
    Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
    Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
    BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Borderline and malignant phyllodes tumors display similar promoter methylation profiles.
    Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
    Virchows Arch; 2009 Dec; 455(6):469-75. PubMed ID: 19924440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of the tumor suppressor PML in human cancers of multiple histologic origins.
    Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP
    J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer.
    Versmold B; Felsberg J; Mikeska T; Ehrentraut D; Köhler J; Hampl JA; Röhn G; Niederacher D; Betz B; Hellmich M; Pietsch T; Schmutzler RK; Waha A
    Int J Cancer; 2007 Aug; 121(3):547-54. PubMed ID: 17415710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
    Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers.
    Virmani A; Rathi A; Heda S; Sugio K; Lewis C; Tonk V; Takahashi T; Roth JA; Minna JD; Euhus DM; Gazdar AF
    Int J Cancer; 2003 Nov; 107(3):341-5. PubMed ID: 14506731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of promoter hypermethylation during breast cancer development.
    Lehmann U; Länger F; Feist H; Glöckner S; Hasemeier B; Kreipe H
    Am J Pathol; 2002 Feb; 160(2):605-12. PubMed ID: 11839581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.